<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0002905'>Hyperphosphatemia</z:hpo>, <z:hpo ids='HP_0002901'>hypocalcemia</z:hpo> and <z:hpo ids='HP_0011009'>acute</z:hpo> oliguric <z:hpo ids='HP_0000083'>renal failure</z:hpo> resulting from <z:chebi fb="3" ids="27226">uric acid</z:chebi> <z:hpo ids='HP_0000112'>nephropathy</z:hpo> developed in a patient with Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and Burkitt cell <z:hpo ids='HP_0001909'>leukemia</z:hpo> after effective chemotherapy </plain></SENT>
<SENT sid="1" pm="."><plain>A review of other reported cases in which the patients had similar <z:mp ids='MP_0005266'>metabolic abnormalities</z:mp> is presented, and the pathophysiology is discussed </plain></SENT>
<SENT sid="2" pm="."><plain>The clinical setting in which these metabolic developments are most likely to occur is defined, and an approach for their prevention and management is presented </plain></SENT>
</text></document>